Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

RTTNews | 290 dni temu
Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

(RTTNews) - While reporting financial results for the third quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings guidance for fiscal 2024, while trimming annual revenue outlook.

For fiscal 2024, the company now projects adjusted earnings in a range of $13.05 to $13.15 per share on revenues growth of about 3.7 percent to about $20.1 billion and adjusted revenues between $20.1 billion to $20.2 billion, with organic revenue growth of 5.0 to 5.25 percent.

Previously, the company expected adjusted earnings in a range of $12.95 to $13.15 per share on revenues between approximately $20.1 billion to $20.3 billion, with organic revenue growth of 6.1 to 7.7 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $13.04 per share on revenue growth of 4.4 percent to $20.23 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
BD Recalls ChloraPrep Clear 1 ML Applicators

BD Recalls ChloraPrep Clear 1 ML Applicators

Medical technology company Becton, Dickinson and Co. or BD has recalled one lot of ChloraPrep Clear 1 mL Applicators citing potential fungal contamination, the U.S. Food and Drug Administration said. Under certain environmental conditions, the contamination allows the growth of Aspergillus penicillioides within the packaging.
RTTNews | 89 dni temu
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

Medical technology company BD or Becton, Dickinson and Co. (BDX) announced Friday the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
RTTNews | 408 dni temu
BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

Medical technology company Becton, Dickinson and Co. or BD (BDX) announced Thursday it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
RTTNews | 528 dni temu
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the second quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | 745 dni temu
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the first quarter on Thursday, medical technology company Becton, Dickinson and Co. or BD (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | 836 dni temu
Sensex, Nifty Seen Lower On US Debt Concerns

Sensex, Nifty Seen Lower On US Debt Concerns

Indian shares look set to open lower on Monday as investors fret about the changing geo-political landscape in India's neighborhood as a new bonhomie between Bangladesh, China and Pakistan takes shape silently.
RTTNews | 19 minut temu